Medexus Pharmaceuticals (TSE:MDP - Get Free Report) was upgraded by research analysts at Alliance Global Partners to a "strong-buy" rating in a report released on Monday,Zacks.com reports.
Medexus Pharmaceuticals Price Performance
TSE:MDP traded up C$0.20 on Monday, reaching C$2.95. The stock had a trading volume of 45,719 shares, compared to its average volume of 73,306. The company has a market cap of C$66.05 million, a price-to-earnings ratio of 14.11 and a beta of 1.96. The firm's fifty day moving average is C$2.92 and its two-hundred day moving average is C$2.80. Medexus Pharmaceuticals has a 12-month low of C$1.71 and a 12-month high of C$5.56.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.
Read More
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
